Last reviewed · How we verify
High intensity therapies
High intensity therapies refer to aggressive, multi-modal treatment regimens combining chemotherapy, radiation, and/or targeted agents to maximize tumor control.
High intensity therapies refer to aggressive, multi-modal treatment regimens combining chemotherapy, radiation, and/or targeted agents to maximize tumor control. Used for Cancer (specific indication not specified in available data).
At a glance
| Generic name | High intensity therapies |
|---|---|
| Sponsor | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
High intensity therapies typically involve dose-escalated or combination chemotherapy protocols, often integrated with radiotherapy and/or targeted biological agents, designed to achieve maximal cytotoxic effect against cancer cells. These approaches are generally employed in early-phase disease or high-risk settings where standard-intensity treatments may be insufficient. The specific mechanism depends on the constituent agents and their molecular targets.
Approved indications
- Cancer (specific indication not specified in available data)
Common side effects
- Hematologic toxicity
- Infection
- Mucositis
- Nausea and vomiting
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Reducing Symptom Burden Through Physical Exercise in Melanoma Patients (NA)
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- New York Better Breathing Study (NA)
- Effectiveness of Combined Super Inductive System (SIS) Therapy With Therapeutic Exercise and Health Education in Lateral Elbow Tendinopathy (NA)
- MRgFUS for Childhood Epilepsy (NA)
- Equal-Volume Pilates Frequency in Women With Overweight and Obesity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: